Kv9 Clinical Trial

To establish safety and efficacy data of in canine solid tumours. 

Including soft tissue sarcomas, mast cell tumours, mammary tumour, anal gland tumour, squamous cell carcinomas, and melanomas.

• No cost treatment option 

• Alternative treatment option for dogs who have already failed or declined surgery

• Possibility of a complete response (no remaining visible tumour) without surgery 

• Possibility of treating tumour masses that have spread to other locations or lymph nodes (metastatic disease) 

• Possibility of reducing the chance of reoccurrence if surgery required

• Your dog must have a diagnosed solid palpable cancer (must be assessed by a veterinarian)​​. ​​

• They must not require urgent complete surgery (>30days)

  • Dogs who have undergone or will undergo surgery will still be considered if they have at least 1cm x 1cm of tumour remaining. 

• They must be expected to survive 3 months minimum

• The tumour is required to be (approximately) greater than minimum size of 1cm x 1cm and there is no minimum or maximum weight for the animal as long as the tumour is of appropriate size.

• The tumour must not have any wounds on the surface.

• They must not be receiving chemotherapy or immunosuppressive drugs, pregnant or lactating. 

• Your dog must not have 3 or more different types of cancers. 

  • This excludes lipomas (fatty masses) and sebaceous adenomas (wart like growth).

Your dog will undergo screening and planning prior to admittance to the study to determine if they fit the eligibility criteria, this includes blood testing if not completed recently. 

​

If enrolled in the study, your dog will receive several small injections (about 0.5mL in total) of a Kv9 solution directly into their tumour mass every 10-14 days (on three occasions).

​

In addition, there will be several follow-ups over the next two years to monitor their disease progression (there will be no charge for these follow-up appointments). The study ends after the last monitoring visit.